Cargando…
Hypothesis for renin-angiotensin inhibitor mitigation of COVID-19
Preexisting hypertension is a known risk factor for severe COVID-19. Abnormal activation of RAS upregulates angiotensin II (Ang-II) and contributes to severe manifestations of COVID-19. Although RAS inhibitors (RASi) are a mainstay of antihypertensive therapy, they have been associated (in some anim...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114589/ https://www.ncbi.nlm.nih.gov/pubmed/34048987 http://dx.doi.org/10.1016/j.mehy.2021.110609 |